Jiangsu Recbio Technology Co., Ltd. (the”Company”, together with its subsidiaries, the “Group”,Stock code:02179.HK) is pleased to announce that, the Company has recently received the clinical trial approval for its recombinant protein COVID-19 vaccine, ReCOV from the Food and Drug Administration of the Philippines, approving the Company to conduct a randomized, blinded, active-controlled Phase II clinical trial of ReCOV on healthy subjects aged 18 years or above who have received primary vaccination with two doses of an inactivated COVID-19 vaccine to compare the immunogenicity and safety between ReCOV and Pfizer’s mRNA vaccine COMIRNATY®. The Company plans to commence clinical enrollment in the near future.
ReCOV is a recombinant COVID-19 vaccine being developed by the Company with its technology platforms including the novel adjuvant and protein engineering platforms, and the adjuvant used therein is the Company’s self-developed novel adjuvant BFA03. Based on the relevant studies conducted by the Company, ReCOV can induce high titers of neutralizing antibody and Th1 biased cellular immune responses, and has shown favorable neutralizing effect and immune persistence against variants including Omicron variant and Delta variant. It has a variety of comprehensive advantages, including overall positive safety profile, potential growth in production scale, low production cost, preparation stability, and ability to be stored and transported at room temperature.
